RT Book, Section
A1 Eschenhagen, Thomas
A2 Brunton, Laurence L.
A2 Hilal-Dandan, Randa
A2 Knollmann, Björn C.
SR Print(0)
ID 1162538503
T1 Therapy of Heart Failure
T2 Goodman & Gilman's: The Pharmacological Basis of Therapeutics, 13e
YR 2017
FD 2017
PB McGraw-Hill Education
PP New York, NY
SN 9781259584732
LK hemonc.mhmedical.com/content.aspx?aid=1162538503
RD 2024/04/19
AB Heart  failure  is  responsible  for  more  than  half  a  million  deaths  annually  in  the  U.S.  Its  prevalence  is  increasing  worldwide,  likely  due  to  improved  survival  of  those  who  have  had  an  acute  myocardial  infarction  and  an  aging  population.  Median  survival  rates  after  the  first  hospitalization  associated  with  heart  failure  are  worse  than  those  of  most  cancers,  but  have  improved  over  the  past  30  years  (1.3  to  2.3  years  in  men  and  1.3  to  1.7  years  in  women)  (Jhund  et  al.,  2009).  This  positive  trend  was  associated  with  a  2-  to  3-fold  higher  prescription  rate  of  ACEIs  and  ARBs,  β  receptor  antagonists  (β  blockers),  and  MRAs,  suggesting  that  improved  drug  therapy  has  contributed  to  enhanced  survival  of  heart  failure.